The protein expression of EZH2 in tumor tissues was reduced in Oe-SPRY4 group but increased in si-SPRY4 group (Figure 7E, 7F), indicating the involvement of EZH2 in the antitumor activity of SPRY4. Immunohistochemistry assay indicated that the expression of Ki67 was remarkably increased upon si-SPRY4, which was also partly declined upon co-treatment of si-SPRY4 and GSK126 (Figure 7G). This evidence concerns the gene SPRY4 and neoplasm.